Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Assets (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Current Assets for 6 consecutive years, with $578.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 28.54% to $578.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $578.3 million, a 28.54% decrease, with the full-year FY2025 number at $578.3 million, down 28.54% from a year prior.
  • Current Assets was $578.3 million for Q4 2025 at Relay Therapeutics, down from $624.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.1 billion in Q3 2022 to a low of $578.3 million in Q4 2025.
  • A 5-year average of $806.7 million and a median of $789.7 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 115.69% in 2021, then dropped 28.54% in 2025.
  • Relay Therapeutics' Current Assets stood at $976.2 million in 2021, then increased by 4.43% to $1.0 billion in 2022, then decreased by 24.46% to $770.1 million in 2023, then rose by 5.08% to $809.2 million in 2024, then decreased by 28.54% to $578.3 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Current Assets are $578.3 million (Q4 2025), $624.0 million (Q3 2025), and $680.4 million (Q2 2025).